| |
Poniard Announces $7.4 Million Financing
Mon 12:15 pm ET (PR Newswire)
Poniard Pharmaceuticals today announced the sale of 3,465,878 of its common shares to Azimuth Opportunity Ltd. for gross proceeds of approximately $7.4 million, or approximately $2.15 per share, under its existing committed equity financing facility with Azimuth.
|
|
Top-Ranked Analysts
|
Provided by StarMine
|
| | |
Locate Industry by Company
|
| Market Capitalization: | 224B | | Price
/ Earnings: | 152.2 | | Price
/ Book: | 7.6 | | Net
Profit Margin (mrq): | 8.6% | | Price
To Free Cash Flow (mrq): | 52.1 | | Return
on Equity: | 6.1% | | Total
Debt / Equity: | 0.0 | | Dividend
Yield: | 2.6% |
|